Brief: Beyondspring Says First Patient Treated In Phase 2 Study With Plinabulin Combined With Nivolumab + Ipilimumab
21/10/2021 13:31
Oct 21 (Reuters) - Beyondspring Inc BYSI.O :
* BEYONDSPRING ANNOUNCES FIRST PATIENT TREATED IN PHASE 2
STUDY
WITH PLINABULIN COMBINED WITH NIVOLUMAB + IPILIMUMAB IN PATIENTS
IN 3RD LINE RECURRENT SMALL-CELL LUNG CANCER PATIENTS WHO FAILED
CHECKPOINT INHIBITORS
Source text for Eikon: ID:nGNXby5BF1
Further company coverage: BYSI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beyondspring
See all newsBrief: Beyondspring Inc Entered Into Open Market Sale Agreement Under Which Co May Offer And Sell Up To 9.2 Million Ordinary Shares
Brief: Beyondspring Announces FDA Fast Track Designation For Plinabulin In Post-Ici Non-Squamous Nsclc And Strategic Transaction To Advance Global Phase 3 Dublin-4 Trial Toward Planned Interim Analysis
NASDAQ RESUMED AT 12:26 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:21 PM
Brief: Beyondspring Announces Leadership Transition To Deliver Focused Execution On Its Confirmatory Dublin-4 Program And Long-Term Value